Category REGENERATIVE MEDICINE

FDA Approves JAK Inhibitor for Moderate to Severe Rheumatoid Arthritis

The FDA approved upadacitinib (Rinvoq, AbbVie), a 15-mg, once-daily oral Janus kinase inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. The approval is supported by data from the SELECT program, one of the largest registrational phase 3 clinical programs

Read More


$9 million grant funds trial of CAR T-cell therapy for metastatic breast cancer

California Institute for Regenerative Medicine awarded a $9.28 million grant will support a clinical trial at City of Hope to evaluate chimeric antigen receptor T-cell therapy for patients with HER2-positive breast cancer that spread to the brain. About 20% of breast cancers are HER2-positive, and nearly half of women with this type of breast cancer develop brain

Read More


Atelerix Consortium Awarded £267,000 Innovate UK Grant for Collaboration with the Cell and Gene Therapy Catapult and Rexgenero on Cell Therapy Stabilisation Technologies

 Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia (CLI), welcomes the news announced today by Atelerix that it has been awarded a grant of £267,000 from Innovate UK. The grant will be used to develop gel stabilisation technologies, developed by Atelerix, with the first objective of extending the

Read More


Gene Editing in Patient-derived Heart Cells May Be Useful in FA

Removal of the genetic defect that causes Friedreich’s ataxia (FA) in heart cells derived from a patient with heart disease associated with FA reversed the cells’ abnormal molecular profile, a study shows. This gene-editing strategy could be a useful tool for regenerative medicine aimed at treating heart defects associated with the condition. The study, “Excision of the

Read More


New Articles in The CRISPR Journal

The CRISPR Journal announces the publication of its August 2019 issue. The Journal is dedicated to validating and publishing outstanding research and commentary on all aspects of CRISPR and gene editing, including CRISPR biology, technology, and genome editing, and commentary and debate of key policy, regulatory, and ethical issues affecting the field. The Journal, led by

Read More